APR 20·PR Newswire▼
CORT SHAREHOLDER ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss
Hagens Berman has announced a securities class action lawsuit against Corcept Therapeutics (CORT) following the FDA's rejection of its lead drug candidate, relacorilant, and a subsequent 50% stock price drop. Investors who suffered significant losses between October 31, 2024, and December 30, 2025, are encouraged to contact the firm before the April 21, 2026, lead plaintiff deadline. The lawsuit alleges that Corcept concealed repeated FDA warnings about insufficient evidence of relacorilant's effectiveness while touting its potential approval.
APR 15·PR Newswire▼
Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Glancy Prongay Wolke & Rotter LLP has announced a securities fraud class action lawsuit against Corcept Therapeutics Incorporated (CORT). Investors who suffered losses between October 31, 2024, and December 30, 2025, have until April 21, 2026, to apply to be lead plaintiffs. The lawsuit alleges that Corcept failed to disclose FDA concerns regarding its relacorilant drug program, leading to "materially misleading and/or lacked a reasonable basis" statements about the company's prospects.
